Skip to main content
. 2019 Nov 8;9:16330. doi: 10.1038/s41598-019-52796-0

Figure 2.

Figure 2

Upregulation of Yy1 suppresses dilated cardiomyopathy induced by Ttn shRNA. (A) Experimental timeline showing timepoints of virus injection and echocardiogram. (B) Ejection fraction (EF), Fractional shortening (FS), left ventricular diastolic dimension (LVDD) and left ventricular wall thickness (LVWT) of mice from control group (control shRNA + EGPF), Ttn shRNA group (Ttn shRNA + EGFP) and Yy1 treated group (Ttn shRNA + Yy1). Virus dose, 0.2E + 13 vg/kg. Cardiac performance was assessed by echocardiogram once a week from 4.5 to 7.5 weeks old. Data were presented as mean and SD, with associated P value, calculated by ANOVA and Tukey’s multiple comparisons test, representing comparison to Ttn shRNA group at each time point, n ≥ 8. (C) Quantitative real-time PCR analysis of Yy1, Nppa, Nppb, Myh7 and Ttn expression in mice from control, Ttn shRNA and Yy1 treated groups at 5.5 weeks old, n ≥ 4. (D) MT of Paraffin sections (left) of mice at 7.5 weeks old, magnification = 4 × , scale bar = 1000 µm, and quantification of myocardial fibrosis (right), n ≥ 4. (E) Quantitative real-time PCR analysis of Yy1 expression in mice injected with control (EGFP) and Yy1 respectively at 21.5 weeks old, virus dose, 0.2E + 13 vg/kg, n = 5.